Gene expression profiles of tumor regression grade in locally advanced rectal cancer after neoadjuvant chemoradiotherapy

  • Authors:
    • Susumu Saigusa
    • Koji Tanaka
    • Yuji Toiyama
    • Kohei Matsushita
    • Mikio Kawamura
    • Yoshinaga Okugawa
    • Junichiro Hiro
    • Yasuhiro Inoue
    • Keiichi Uchida
    • Yasuhiko Mohri
    • Masato Kusunoki
  • View Affiliations

  • Published online on: June 14, 2012     https://doi.org/10.3892/or.2012.1863
  • Pages: 855-861
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Tumor regression grading (TRG) reportedly has prognostic value in rectal cancer patients after pre-operative chemoradiotherapy (CRT). The aim of this retrospective study was to differentiate gene expression profiles based on TRG in residual cancer cells after CRT. We evaluated pathological response using the criteria of four TRG systems: the Japanese Society for the Cancer of Colon and Rectum (JSCCR), Mandard, Dworak and Rödel. Total RNA was obtained using microdissection from 52 locally advanced rectal cancer specimens from patients who underwent pre-operative CRT to examine the expression levels of 20 genes [PCNA, MKI67, CDKN1A (p21Cip1), CDK2, CHEK1, PDRG1, LGR5, PROM1 (CD133), CD44, SOX2, POU5F1 (OCT4), LKB1, VEGF, EGFR, HGF, MET, HIF1, GLUT1, BAX and BCL2] using real-time quantitative RT-PCR. Gene expression was compared across the four TRG systems. LGR5 gene expression levels in CRT non-responders were significantly higher than in responders in all four grading systems. Patients with elevated PDRG1 and GLUT1 gene expression had poor pathological response in three TRG systems (JSCCR, Dworak and Rödel). MKI67 gene expression in non-responders was significantly higher than in responders in two grading systems (JSCCR and Rödel). While, BAX gene expression in responders was significantly higher than in non-responders in the Mandard TRG system. The results of this study suggest that TRG may reflect characteristics, such as proliferative activity, stemness potency and resistance to hypoxia, of residual cancer cells following pre-operative CRT.
View Figures
View References

Related Articles

Journal Cover

September 2012
Volume 28 Issue 3

Print ISSN: 1021-335X
Online ISSN:1791-2431

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Saigusa S, Tanaka K, Toiyama Y, Matsushita K, Kawamura M, Okugawa Y, Hiro J, Inoue Y, Uchida K, Mohri Y, Mohri Y, et al: Gene expression profiles of tumor regression grade in locally advanced rectal cancer after neoadjuvant chemoradiotherapy. Oncol Rep 28: 855-861, 2012
APA
Saigusa, S., Tanaka, K., Toiyama, Y., Matsushita, K., Kawamura, M., Okugawa, Y. ... Kusunoki, M. (2012). Gene expression profiles of tumor regression grade in locally advanced rectal cancer after neoadjuvant chemoradiotherapy. Oncology Reports, 28, 855-861. https://doi.org/10.3892/or.2012.1863
MLA
Saigusa, S., Tanaka, K., Toiyama, Y., Matsushita, K., Kawamura, M., Okugawa, Y., Hiro, J., Inoue, Y., Uchida, K., Mohri, Y., Kusunoki, M."Gene expression profiles of tumor regression grade in locally advanced rectal cancer after neoadjuvant chemoradiotherapy". Oncology Reports 28.3 (2012): 855-861.
Chicago
Saigusa, S., Tanaka, K., Toiyama, Y., Matsushita, K., Kawamura, M., Okugawa, Y., Hiro, J., Inoue, Y., Uchida, K., Mohri, Y., Kusunoki, M."Gene expression profiles of tumor regression grade in locally advanced rectal cancer after neoadjuvant chemoradiotherapy". Oncology Reports 28, no. 3 (2012): 855-861. https://doi.org/10.3892/or.2012.1863